HiberGene Casts Net Wide For Series B Funding
Executive Summary
From crowdfunding to taking on its distributor partner as investor, the varied fundraising routes that HiberGene traveled down for its series B round has enabled the Irish rapid molecular diagnostic test developer to raise €6.7m.
You may also be interested in...
HiberGene's Rapid Group B Strep Test Pregnant With Potential
A year after launching its first product, rapid molecular diagnostics specialist HiberGene now has a trio of infectious diseases tests under its belt. One of the tests, designed to detect Group B Streptococcus in pregnant women, is expected to be a major cash generator for the firm once it begins its sales ramp-up.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.